Previous studies on the relationship between metformin therapy and prostate cancer risk have yielded conflicting results. Cancer researchers are not sure how to explain these findings. In recent years, new evidence suggested that the effect of metformin on prostate cancer risk might vary in different ethnicities. As we enter the era of precision medicine, to clarify the effect of metformin on cancer risk, race-specific molecular factors should be considered and incorporated into future prostate cancer studies.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Cancer prevention research (Philadelphia, Pa.). 2016 Jul 18 [Epub ahead of print]
Edward Uchio, Frank L Meyskens, Ping H Wang
Urology, University of California, Irvine., Chao Family Comprehensive Cancer Center, University of California Irvine., Medicine, University of California, Irvine .